Navigation Links
Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
Date:5/11/2009

CAMBRIDGE, Mass., May 11 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the upcoming Deutsche Bank 2009 Health Care Conference on Monday, May 18, 2009 at 8:40 a.m. ET at the Intercontinental Hotel, Boston.

The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conference.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus. For further information about Idenix, please refer to http://www.idenix.com.

    Idenix Pharmaceuticals Contact:
    Teri Dahlman 617-995-9905


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Idenix Pharmaceuticals Reports First Quarter Financial Results
2. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
3. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
4. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
5. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
6. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
7. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
8. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
9. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
10. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
11. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... AUSTIN, Texas, March 29, 2017  Vermillion, Inc. ... gynecologic disease, reported on its results for the ... 2016. "2016 marked a pivotal year ... ACOG guideline inclusion, international distribution agreements, major reimbursement ... in network payer agreements. In addition we cleared ...
(Date:3/29/2017)... - Last year,s petition to the White House signed by ... to generate awareness on the importance of new organic medicines and ... market place. ... Earlier this month Health Advance (OTC PINK: HADV ... products, announced its endeavors on this generally recognized as safe ...
(Date:3/29/2017)... ... March 29, 2017 , ... (March ... International Mexico has been approved as an active member of the Mexican ... protection among distributers and consumers in relationship marketing. This professional organization fosters loyal ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
Breaking Biology News(10 mins):